… This review aims to offer a pathogenetic rationale behind current therapies, briefly … pulmonary
fibrosis, which may ultimately lead to the development of novel and effective therapeutic …

… fibrotic responses.[40,42] The plausible mechanisms orchestrating the fibrotic process in IPF
and potential novel therapeutic … historical and conventional therapeutic approaches to this …

… Other therapies either alone or in combination with corticosteroids are widely used, … In
conclusion, at present, there are no evidence-based therapies for idiopathic pulmonary fibrosis. …

Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic … therapies are most likely to
be effective early in the course of disease, before the development of irreversible fibrosis. In a …

… in the pathogenesis of pulmonary fibrosis as well as the evidence of oxidative stress in
human IPF with emphasis on the pharmacological approach targeting oxidative stress. …

… Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that
is associated with a median survival of 2-3 years from initial diagnosis. To date, there is no …

… approaches based on genomic and proteomic information in order to identify subjects who
would benefit from individually tailored therapeutic … impact on therapeutic approaches. The …

… Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease associated
… In addition to pharmacological therapy, optimal management of IPF includes treatment of …

… To improve clinical outcomes, researchers are pursuing alternative therapeutic approaches
to fibrogenesis and its resolution, especially drugs targeting the signaling pathways that …

… Despite constant efforts, many therapeutic approaches failed until antifibrotic therapy
fundamentally altered the therapeutic approach in IPF (figure 1). Currently, two antifibrotic therapies …